CD8A and neoplasm: All formulations tested, i.e. admixed and entrapped SLA archaeosomes and encapsulated natural archaeosomes presenting OVA, enhanced the effects of checkpoint inhibition therapy by increasing the survival rate of mice and OVA-CD8+ T cell production and by reducing tumor growth in comparison to checkpoint inhibition therapy alone (29).